UCB SA 2024 IR
The report outlines UCB's financial and business performance for the fiscal year 2024, highlighting a 17% revenue growth to €6,152 million driven by key growth products like Bimzelx and Fintepla. It details strategic milestones, including the divestment of UCB's mature neurology and allergy portfolio in China and the validation of its net-zero targets by the Science Based Targets initiative (SBTi). Additionally, the report provides comprehensive updates on UCB's clinical development pipeline and regulatory approvals across global markets.
Company: UCB SA
Sector: Health Care
Country: Belgium
Year: 2024
Type: IR
Pages: 25
UCB SA
Integrated Annual Report
The report outlines UCB's financial and business performance for the fiscal year 2024, highlighting a 17% revenue growth to €6,152 million driven by key growth products like Bimzelx and Fintepla. It details strategic milestones, including the divestment of UCB's mature neurology and allergy portfolio in China and the validation of its net-zero targets by the Science Based Targets initiative (SBTi). Additionally, the report provides comprehensive updates on UCB's clinical development pipeline and regulatory approvals across global markets.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
No data available